NTRC announces approval of key TTK kinase inhibitor patent
NTRC today announced that the USPTO has granted patent protection for a key patent for its TTK kinase inhibitor programme.
Read more
Start-up Talent Transmitter opent zijn deuren op het Pivot Park in Oss
Per 18 september vestigt Talent Transmitter zich op het Pivot Park in Oss.
Read more
New at Pivot Park – GenTac
GenTac, joining the Pivot Park community in September, provides the tactical and strategic tools of transnational communications to industry, institutions, agencies, publications and nonprofit organizations worldwide.
Read more
Step closer to Q-fever vaccine
The development of a new Q-fever vaccine is a little closer to realisation. InnatOss is developing this Q-fever vaccine.
Read more
Ceres InnatOss to Launch the Nanotrap® Lyme Antigen Test in the EU
Ceres and Innatoss announced today a partnership that will deliver the Nanotrap® Lyme Antigen Test in the EU.
Read more
Genomic drug sensitivity biomarker for TTK inhibitors published in Molecular Cancer Therapeutics
In a new publication, NTRC scientists propose mutations in the cancer hot spot region of the β-catenin gene (CTNNB1) as prognostic drug sensitivity biomarkers for TTK inhibitors.
Read more
New at Pivot Park – Atro Medical
ATRO Medical is focusing their R&D activities on the meniscus prothesis Trammpolin™.
Read more
NTRC expands Oncolines™ cell line panel to 102 cell lines
NTRC has launched an expansion of its Oncolines™ cancer cell line panel, from 66 to 102 cell lines.
Read more
Successful first-in-human study exploiting a unique scalable Natural Killer-cell product
We report the first-in-human study exploiting a unique scalable NK-cell product generated ex vivo from CD34+ hematopoietic stem and progenitor cells (HSPC) from partially HLA-matched umbilical cord blood units.
Read more